Table 1.
Characteristics of the study population (n = 275)
| Parameter | Value |
|---|---|
| Age (years)a | 44 (42–48) |
| Male gender, no. (%) | 245 (89) |
| Daily alcohol intake > 50 grs/day, no. (%) | 40 (14) |
| Previous intravenous drug users, no. (%) | 250 (91) |
| Previous therapy against HCV, no (%) | 57 (21) |
| HCV genotype, no. (%)b | |
| 1 | 165 (61) |
| 2 | 2 (1) |
| 3 | 61 (23) |
| 4 | 41 (15) |
| HCV RNA load (log10 IU/mL)a,c | 6.17 (5.68–6.69) |
| Positive hepatitis B virus surface antigen, no (%) | 8 (3) |
| Serum alanine aminotransferase (IU/L)a | 74 (48–105) |
| Serum aspartate aminotransferase (IU/L)a | 72 (47–104) |
| Total bilirrubin (mg/dL)a | 0.7 (0.5–1.02) |
| Platelet count (/mm3)a | 130000 (94000–171750) |
| HIV RNA load < 50 copies/mL, no. (%) | 184 (67) |
| CD4 cells/mLa | 459 (265–626) |
| ARTd, no (%) | 256 (83) |
| MELDe scorea,f | 7 (6–9) |
| Child-Turcotte-Pugh class, no (%) | |
| A | 248 (90) |
| B | 27 (10) |
| Liver stiffness (kPa)a | 20 (17–27) |
aMedian (Q1-Q3)
Available in b269 and
c254 patients
dART: Antiretroviral therapy
eMELD: Model for end-stage liver disease
fAvailable in 251 patients